Virology:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

       

      Hepatitis C

       
      Maviret

       

      The World Health Organization
      is working to eliminate Hep C by 2030.*1,2

       
      The Welsh government has pledged to eliminate Hep C by 2030,
      whilst NHS England aims to eliminate Hep C by       2025,
      and the Scottish government is aiming for 2024.2-4
       
      Elimination of Hep C in the UK is possible, let’s make it a reality.

       

      >71,000,000

      people infected

      worldwide1

       

       

      Only 1 in 5

      infected people

      aware of their

      infection1

       

       

      95% cases

      curable with

      modern antiviral

      therapies1

       

      Why choose Maviret for community treatment?

      Pangenotypic6,7

      • Simplifies the treatment pathway, allowing more patients to be treated

      8-week treatment duration for treatment-naïve patients6,2

      • Ideal for community-based settings, particularly for patients who may be difficult to engage

      Once-daily regimen6

      • No minimum calorie requirements or additional ribavirin
      • No baseline or viral load testing
      • No need to routinely monitor liver function

      Maviret indication6

      Maviret is indicated for the treatment of chronic hepatitis C virus (HCV) infection, genotypes 1-6, in adults and in adolescents aged 12 to <18 years with compensated liver disease. Maviret may be used for a minimum of 12 weeks in liver and kidney transplant recipients - see SmPC for specific genotypes.

       

      *Elimination defined by WHO as achieving 90% reduction in new chronic infections and a 65% reduction in mortality due to viral hepatitis.1

      AE = adverse event.

      References:

      1. The World Health Organization (WHO). Hepatitis C. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (accessed December 2020).
      2. All-Party Parliamentary Group on Liver Health Inquiry Report. Eliminating Hepatitis C in England. March 2018. Available at: www.appghep.org.uk/reports/ (accessed December 2020).
      3. NHS England NHS England sets out plans to be first in the world to eliminate Hepatitis C. 29 January 2018. Available at: www.england.nhs.uk/2018/01/hepatitis-c-2/ (accessed December 2020).
      4. Scottish Government. Eliminating hepatitis C. 31 July 2019. Available at: www.gov.scot/news/eliminating-hepatitis-c/ (accessed December 2020).
      5. Ward JW. The Lancet 2020; DOI: https://doi.org/10.1016/S0140-6736(20)32282-0 (accessed December 2020).
      6. Maviret Summary of Product Characteristics. AbbVie Ltd. Available at: www.medicines.org.uk
      7. European Association for the Study of the Liver. J Hepatol. 2018; 69(2): 461−511.
       
      MAVIRET ADVERSE EVENT REPORTING AND PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk .
      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      UK-MAVI-210016. Date of preparation: March 2021